NEWSROOM

Healthcare

Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms

Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms

Dec 2, 2024

Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population Study shows that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies Early detection of transplant rejection is growing in significance as novel therapeutic treatments show promising early results in antibody mediated rejection. Study published in Nephrology Dialysis...

Halberd Update on WatchDawg® PTSD Treatment

Halberd Update on WatchDawg® PTSD Treatment

Dec 2, 2024

Next Phase Pilot Study Jackson Center, PA, December 2, 2024 - PRISM MediaWire - Halberd Corporation (OTC PINK: HALB) previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. The results of that study can be found here. Based on the encouraging results of that initial pilot study, upgrades and enhancements to the data collection methodology, data analysis, hardware, software...

SS Innovations Marks a Milestone with First Robotic Cardiac Surgery in Indonesia

SS Innovations Marks a Milestone with First Robotic Cardiac Surgery in Indonesia

Nov 26, 2024

SS Innovations marks a milestone with the successful completion of Indonesia’s first robotic cardiac surgery using its SSi Mantra Surgical Robotic System. Dr. Sudhir Srivastava, Founder, Chairman, and CEO of SS Innovations successfully performed the first Beating Heart Totally Endoscopic Coronary Artery Bypass (TECAB) in Indonesia, a significant achievement in the field of robotic cardiac surgery. The developed and made-in-India SSi Mantra Surgical Robotic System highlights India’s position as...

BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts

BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts

Nov 25, 2024

Company continues to advance its placental-derived product portfolio with the first patent granted in the fenestrated wound care market POMPANO BEACH, Fla., Nov. 25, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for...

BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global

BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global

Nov 20, 2024

Additions of ProgenaMatrix®and revyve™ Antimicrobial Wound Gel part of planned expansion of BioStem’s commercial product portfolio POMPANO BEACH, Fla., November 20, 2024 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics, today announced the signing of a Letter of Intent (LOI) to acquire commercial-stage products and development technologies from ProgenaCare Global...

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Nov 13, 2024

Company advancing late-stage clinical programs with novel therapies that target underserved heart diseases NEW YORK, November 13, 2024 - PRISM MediaWire - PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL) has been added to the PRISM Emerging Biotech Index, which spotlights companies leading innovation and creating market impact within the biotech sector. Cardiol’s focus on anti-inflammatory and...

American Shared Hospital Services Reports Third Quarter 2024 Financial Results

American Shared Hospital Services Reports Third Quarter 2024 Financial Results

Nov 13, 2024

- Revenue increases 36.3% period over period - Conference Call on November 13th at 1:00 pm ET SAN FRANCISCO, CA, November 13, 2024 ‒ American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and services, today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Recent Highlights Total revenue in...

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025

Nov 12, 2024

Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed on to use GraftAssure kitted research test in early launch phase FDA pre-submission process for approval of kitted clinical test is underway IRVINE, Calif., Nov. 12, 2024 - PRISM MediaWire - Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today published the following letter to shareholders in conjunction with its third...

PPJ Healthcare Enterprises Expands Business with New Health & Wellness Franchises

PPJ Healthcare Enterprises Expands Business with New Health & Wellness Franchises

Nov 12, 2024

TAMPA, Florida, November 12, 2024 - PRISM MediaWire - PPJ Healthcare Enterprises Inc. (OTC Pink: PPJE) announces today that the company is adding Health and Wellness Franchises to its business plans. Ms. Basu noted: "Our company has invested several years in research and development of innovative health and wellness services to provide effective relief for Americans facing undiagnosed conditions. We are excited to introduce various franchise options and are on track to launch our first center...

BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts

BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million

Nov 12, 2024

Company reports third sequential quarter of record growth, contributing to a record total of $199.0 million in revenue for the first nine-months of 2024 Achieves third consecutive quarter of positive GAAP net income of $6.8 million or $0.42 per share. Generated Q3 2024 Adjusted EBITDA of $9.9 million Financial Results Conference Call and Webcast on Tuesday, November 12, 2024, at 4:30 pm ET POMPANO BEACH, FL, November 12, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (the...

Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

Nov 12, 2024

PITTSBURGH, November 12, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that U.S. Patent No. 12,138,345 for its proprietary liposomal drug delivery platform will be officially issued by the U.S. Patent and Trademark Office (USPTO) on November 12, 2024. This patent, titled "Delivery of Agents Using Metastable Liposomes," covers...

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Nov 6, 2024

Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m. ET IRVINE, Calif., Nov. 6, 2024 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. The company will also host a conference call and webcast on Tuesday, November 12, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss...

American Shared Hospital Services Reports Third Quarter 2024 Financial Results

American Shared Hospital Services Announces Third Quarter 2024 Earnings Conference Call

Nov 6, 2024

Call Scheduled November 13th at 1:00 PM ET SAN FRANCISCO, November 6, 2024 - PRISM MediaWire - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a conference call to discuss its third quarter 2024 financial results on November 13th at 1:00 pm ET / 10:00 am PT. The third quarter 2024 financial...

Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Nov 1, 2024

PITTSBURGH, PA, November 1, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the “Company,” “our” or “us”), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company’s certificate of...

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

Oct 29, 2024

The pricing announcement from the Center for Medicare Services became effective on October 1, 2024, and allows BioStem to begin marketing initiatives with Venture Medical POMPANO BEACH, Fla., October 29, 2024 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces it will initiate a nationwide launch of Vendaje AC® with Venture Medical,...

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 28, 2024

Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., October 28, 2024 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that it will release its Third quarter 2024 financial results on Tuesday, November 12, 2024, and host a conference call and webcast at 4:30 PM ET to discuss the results. The webcast will...

NeuroOne® Medical Technologies to Present at the 2024 ThinkEquity Conference

NeuroOne® Medical Technologies to Present at the 2024 ThinkEquity Conference

Oct 24, 2024

EDEN PRAIRIE, Minn., October 24, 2024 - PRISM MediaWire - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate...

Soligenix, Inc. to Present at the 2024 ThinkEquity Conference

Soligenix, Inc. to Present at the 2024 ThinkEquity Conference

Oct 24, 2024

Princeton, NJ, October 24, 2024 - PRISM MediaWire - Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other...

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

Oct 23, 2024

Glen Allen, VA, October 23, 2024 - PRISM MediaWire - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024

Oct 23, 2024

MIAMI, FL., October 23, 2024 – PRISM MediaWire - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, (“NRx,” the “Company”) and HOPE Therapeutics, Inc., a medical and technology driven company and wholly-owned subsidiary of NRx, today announced they will be featured as a participating in the ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate...

Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor

Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor

Oct 23, 2024

Discoverer of Klotho gene further strengths KLTO Scientific Advisory Board New York, NY, October 23, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a leading biotechnology company focused on developing cell and gene therapies for aging and age-related diseases, is proud to announce the appointment of Dr. Makoto Kuro-o to its Scientific Advisory Board. Dr. Kuro-o, a distinguished Japanese physician-scientist, is widely recognized as the pioneer behind the discovery of the...

Innocan Pharma to Present at the 2024 ThinkEquity Conference

Innocan Pharma to Present at the 2024 ThinkEquity Conference

Oct 21, 2024

Herzliya, Israel and Calgary, Alberta, October 21, 2024 - PRISM MediaWire - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in chronic pain management via Liposomal CBD drug products, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry...

Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference

Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference

Oct 18, 2024

NEWTOWN, Pa., Oct. 18, 2024 - PRISM MediaWire - Helius Medical Technologies, Inc. (“Helius” or the “Company”) [Nasdaq: HSDT], a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it plans to participate in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals...

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment

Oct 17, 2024

Retrospective Study demonstrates clinical efficacy and statistical support for tissue processed via BioREtain to care for treatment-resistant chronic wounds Study published in the peer-reviewed journal, ‘International Wound Journal’ POMPANO BEACH, Fla., Oct. 17, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived biologics for advanced wound care, announces breakthrough...

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Oct 16, 2024

IRVINE, Calif., Oct. 16, 2024 - PRISM MediaWire - Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles. Oncocyte management will also be available for one-on-one meetings with investors. To schedule a one-on-one meeting, please contact Julie Silber at PCG Advisory (jsilber@pcgadvisory.com) or request a meeting via the LD Micro...

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions

Oct 15, 2024

Vendaje AC to launch across MAC regions nationwide through Venture Medical, the Company’s exclusive sales and marketing partner for AmnioWrap2® POMPANO BEACH, Fla., Oct. 15, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that the Center for Medicare Services (CMS) has established national pricing for its allograft...

Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor

Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences

Oct 15, 2024

KLTO strengthens team with industry veteran and is poised to accelerate the development of its therapeutic candidates New York, NY, October 15, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for aging and age-related diseases, today announced the appointment of Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its Chief Operating Officer (COO). “We are thrilled to have Peter join Klotho...

Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform

Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform

Oct 15, 2024

Patent application covers key technology innovations for delivering therapeutic agents Proprietary technology enables precise delivery to improve safety and efficacy in oncology, cancer survivorship and immunotherapy Allowance provides broad IP protection for drug-delivery platform and extends market exclusivity for two lead clinical assets currently in Phase 2 trials PITTSBURGH, PA, October 15, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage...

In Light of World Mental Health Day, PRISM Highlights Mental Health Index Companies Making a Difference

In Light of World Mental Health Day, PRISM Highlights Mental Health Index Companies Making a Difference

Oct 10, 2024

New York, New York, October 10, 2024 - PRISM MediaWire - PRISM MediaWire - Mental health has not always been a topic to discuss as easily as other health related topics due to the stigma surrounding it. Those who have identified having a mental health condition typically do not seek the proper help or treatment for fear of judgement or admission to being unstable. The reality of it is that whether or not you have a condition, we all need to do things to ensure we have good mental health in the...

Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

Oct 8, 2024

Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO targets a multi-billion-dollar addressable market in oncology diagnostics IRVINE, Calif., October 8, 2024 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed publication of positive data related to its proprietary gene expression test,...